The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
High Frequency of Mutations of the PIK3CA Gene in Human Cancers
Abstract
3,1232,680MetricsTotal Downloads3,123Last 6 Months470Last 12 Months1,013Total Citations2,680Last 6 Months51Last 12 Months112View all metrics
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The phosphatidylinositol 3-Kinase–AKT pathway in human cancer
Vivanco, I., & Sawyers, C. L. (2002) · Nature Reviews Cancer · doi:10.1038/nrc839 · Cited by 6,056
PIK3CA is implicated as an oncogene in ovarian cancer
Shayesteh, L., Lu, Y., Kuo, W.-L., Baldocchi, R., Godfrey, T., Collins, C., Pinkel, D., Powell, B., Mills, G. B., & Gray, J. W. (1999) · Nature Genetics · doi:10.1038/5042 · Cited by 1,155
Prevalence of somatic alterations in the colorectal cancer cell genome
Wang, T.-L., Rago, C., Silliman, N., Ptak, J., Markowitz, S., Willson, J. K. V., Parmigiani, G., Kinzler, K. W., Vogelstein, B., & Velculescu, V. E. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.261714699 · Cited by 177
Self-citation(1998) · Pure Amsterdam UMC · doi:10.1002/(sici)1097-0142(19980701)83:1 · Cited by 3
Cited by
Items 101–200 of 344
Cancer genomics: from discovery science to personalized medicine
Chin, L., Andersen, J. N., & Futreal, P. A. (2011) · Nature Medicine · doi:10.1038/nm.2323 · Cited by 644
Pao, W., & Miller, V. A. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.07.799 · Cited by 631
Therapeutic targeting of the angiopoietin–TIE pathway
Saharinen, P., Eklund, L., & Alitalo, K. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.278 · Cited by 620
Chapter 2 PI3K/PTEN Signaling in Angiogenesis and Tumorigenesis
(2009) · Advances in Cancer Research · doi:10.1016/s0065-230x(09)02002-8 · Cited by 620
Integrative Genomic Approaches Identify IKBKE as a Breast Cancer Oncogene
Boehm, J. S., Zhao, J. J., Yao, J., Kim, S. Y., Firestein, R., Dunn, I. F., Sjostrom, S. K., Garraway, L. A., Weremowicz, S., Richardson, A. L., et al. (2007) · Cell · doi:10.1016/j.cell.2007.03.052 · Cited by 617
Pathways of Colorectal Carcinogenesis
Nguyen, L. H., Goel, A., & Chung, D. C. (2020) · Gastroenterology · doi:10.1053/j.gastro.2019.08.059 · Cited by 606
Mutations in a signalling pathway
Parsons, D. W., Wang, T.-L., Samuels, Y., Bardelli, A., Cummins, J. M., DeLong, L., Silliman, N., Ptak, J., Szabo, S., Willson, J. K. V., et al. (2005) · Nature · doi:10.1038/436792a · Cited by 599
Self-citationClass I PI3K in oncogenic cellular transformation
Zhao, L., & Vogt, P. K. (2008) · Oncogene · doi:10.1038/onc.2008.244 · Cited by 594
Brognard, J., Sierecki, E., Gao, T., & Newton, A. C. (2007) · Molecular Cell · doi:10.1016/j.molcel.2007.02.017 · Cited by 591
Convergent loss of PTEN leads to clinical resistance to a PI(3)Kα inhibitor
Juric, D., Castel, P., Griffith, M., Griffith, O. L., Won, H. H., Ellis, H., Ebbesen, S. H., Ainscough, B. J., Ramu, A., Iyer, G., et al. (2015) · Nature · doi:10.1038/nature13948 · Cited by 588
A dual PI3 kinase/mTOR inhibitor reveals emergent efficacy in glioma
Fan, Q.-W., Knight, Z. A., Goldenberg, D. D., Yu, W., Mostov, K. E., Stokoe, D., Shokat, K. M., & Weiss, W. A. (2006) · Cancer Cell · doi:10.1016/j.ccr.2006.03.029 · Cited by 585
Luks, V. L., Kamitaki, N., Vivero, M. P., Uller, W., Rab, R., Bovée, J. V. M. G., Rialon, K. L., Guevara, C. J., Alomari, A. I., Greene, A. K., et al. (2015) · The Journal of Pediatrics · doi:10.1016/j.jpeds.2014.12.069 · Cited by 583
Heger, M., van Golen, R. F., Broekgaarden, M., & Michel, M. C. (2014) · Pharmacological Reviews · doi:10.1124/pr.110.004044 · Cited by 576
The Structure of a Human p110α/p85α Complex Elucidates the Effects of Oncogenic PI3Kα Mutations
Huang, C.-H., Mandelker, D., Schmidt-Kittler, O., Samuels, Y., Velculescu, V. E., Kinzler, K. W., Vogelstein, B., Gabelli, S. B., & Amzel, L. M. (2007) · Science · doi:10.1126/science.1150799 · Cited by 560
Self-citationRegulating the regulator: post-translational modification of RAS
Ahearn, I. M., Haigis, K., Bar-Sagi, D., & Philips, M. R. (2012) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3255 · Cited by 557
Genomics and Signaling Pathways in Hepatocellular Carcinoma
Villanueva, A., Newell, P., Chiang, D., Friedman, S., & Llovet, J. (2007) · Seminars in Liver Disease · doi:10.1055/s-2006-960171 · Cited by 556
Steelman, L. S., Chappell, W. H., Abrams, S. L., Kempf, C. R., Long, J., Laidler, P., Mijatovic, S., Maksimovic-Ivanic, D., Stivala, F., Mazzarino, M. C., et al. (2011) · Aging · doi:10.18632/aging.100296 · Cited by 553
Targeting phosphoinositide 3-kinase—Moving towards therapy
Marone, R., Cmiljanovic, V., Giese, B., & Wymann, M. P. (2008) · Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics · doi:10.1016/j.bbapap.2007.10.003 · Cited by 548
PTEN-deficient cancers depend on PIK3CB
Wee, S., Wiederschain, D., Maira, S.-M., Loo, A., Miller, C., deBeaumont, R., Stegmeier, F., Yao, Y.-M., & Lengauer, C. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0802655105 · Cited by 545
DJ-1, a novel regulator of the tumor suppressor PTEN
Kim, R. H., Peters, M., Jang, Y., Shi, W., Pintilie, M., Fletcher, G. C., DeLuca, C., Liepa, J., Zhou, L., Snow, B., et al. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.02.010 · Cited by 544
Targeting the PI3K–AKT–mTOR pathway: progress, pitfalls, and promises
Yap, T. A., Garrett, M. D., Walton, M. I., Raynaud, F., de Bono, J. S., & Workman, P. (2008) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2008.08.004 · Cited by 543
PI3K/Akt/mTOR signaling pathway and targeted therapy for glioblastoma
Li, X., Wu, C., Chen, N., Gu, H., Yen, A., Cao, L., Wang, E., & Wang, L. (2016) · Oncotarget · doi:10.18632/oncotarget.7961 · Cited by 542
Signalling through Class I PI3Ks in mammalian cells
Hawkins, P. T., Anderson, K. E., Davidson, K., & Stephens, L. R. (2006) · Biochemical Society Transactions · doi:10.1042/bst0340647 · Cited by 540
Personalized Medicine in a Phase I Clinical Trials Program: The MD Anderson Cancer Center Initiative
Tsimberidou, A.-M., Iskander, N. G., Hong, D. S., Wheler, J. J., Falchook, G. S., Fu, S., Piha-Paul, S., Naing, A., Janku, F., Luthra, R., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-1627 · Cited by 539
Oncogenic Mutations of PIK3CA in Human Cancers
Samuels, Y., & Velculescu, V. E. (2004) · Cell Cycle · doi:10.4161/cc.3.10.1164 · Cited by 538
Self-citationSomatic Mosaic Activating Mutations in PIK3CA Cause CLOVES Syndrome
Kurek, K. C., Luks, V. L., Ayturk, U. M., Alomari, A. I., Fishman, S. J., Spencer, S. A., Mulliken, J. B., Bowen, M. E., Yamamoto, G. L., Kozakewich, H. P. W., et al. (2012) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2012.05.006 · Cited by 532
Maira, S.-M., Pecchi, S., Huang, A., Burger, M., Knapp, M., Sterker, D., Schnell, C., Guthy, D., Nagel, T., Wiesmann, M., et al. (2012) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-11-0474 · Cited by 529
Targeting the PI3K/Akt/mTOR pathway in non‐small cell lung cancer (NSCLC)
Tan, A. C. (2020) · Thoracic Cancer · doi:10.1111/1759-7714.13328 · Cited by 528
Clinical management of metastatic colorectal cancer in the era of precision medicine
Ciardiello, F., Ciardiello, D., Martini, G., Napolitano, S., Tabernero, J., & Cervantes, A. (2022) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21728 · Cited by 528
Genetic heterogeneity of diffuse large B-cell lymphoma
Zhang, J., Grubor, V., Love, C. L., Banerjee, A., Richards, K. L., Mieczkowski, P. A., Dunphy, C., Choi, W., Au, W. Y., Srivastava, G., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1205299110 · Cited by 527
AKT-Independent Signaling Downstream of Oncogenic PIK3CA Mutations in Human Cancer
Vasudevan, K. M., Barbie, D. A., Davies, M. A., Rabinovsky, R., McNear, C. J., Kim, J. J., Hennessy, B. T., Tseng, H., Pochanard, P., Kim, S. Y., et al. (2009) · Cancer Cell · doi:10.1016/j.ccr.2009.04.012 · Cited by 524
Oncogenic PI3K and its role in cancer
Samuels, Y., & Ericson, K. (2006) · Current Opinion in Oncology · doi:10.1097/01.cco.0000198021.99347.b9 · Cited by 521
Self-citationBreast Cancer–Associated PIK3CA Mutations Are Oncogenic in Mammary Epithelial Cells
Isakoff, S. J., Engelman, J. A., Irie, H. Y., Luo, J., Brachmann, S. M., Pearline, R. V., Cantley, L. C., & Brugge, J. S. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-2612 · Cited by 509
PIK3CA gene is frequently mutated in breast carcinomas and hepatocellular carcinomas
Lee, J. W., Soung, Y. H., Kim, S. Y., Lee, H. W., Park, W. S., Nam, S. W., Kim, S. H., Lee, J. Y., Yoo, N. J., & Lee, S. H. (2005) · Oncogene · doi:10.1038/sj.onc.1208304 · Cited by 506
Mutation of the PIK3CA oncogene in human cancers
Karakas, B., Bachman, K. E., & Park, B. H. (2006) · British Journal of Cancer · doi:10.1038/sj.bjc.6602970 · Cited by 505
Genetics and Genetic Biomarkers in Sporadic Colorectal Cancer
Carethers, J. M., & Jung, B. H. (2015) · Gastroenterology · doi:10.1053/j.gastro.2015.06.047 · Cited by 483
Ligon, K. L., Huillard, E., Mehta, S., Kesari, S., Liu, H., Alberta, J. A., Bachoo, R. M., Kane, M., Louis, D. N., DePinho, R. A., et al. (2007) · Neuron · doi:10.1016/j.neuron.2007.01.009 · Cited by 501
Eichhorn, P. J. A., Gili, M., Scaltriti, M., Serra, V., Guzman, M., Nijkamp, W., Beijersbergen, R. L., Valero, V., Seoane, J., Bernards, R., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-1740 · Cited by 499
Frequent Activating Mutations of PIK3CA in Ovarian Clear Cell Carcinoma
Kuo, K.-T., Mao, T.-L., Jones, S., Veras, E., Ayhan, A., Wang, T.-L., Glas, R., Slamon, D., Velculescu, V. E., Kuman, R. J., et al. (2009) · The American Journal of Pathology · doi:10.2353/ajpath.2009.081000 · Cited by 485
Self-citationPTEN Tumor Suppressor Network in PI3K-Akt Pathway Control
Georgescu, M.-M. (2010) · Genes & Cancer · doi:10.1177/1947601911407325 · Cited by 482
Rac1 Activation Controls Nuclear Localization of β-catenin during Canonical Wnt Signaling
Wu, X., Tu, X., Joeng, K. S., Hilton, M. J., Williams, D. A., & Long, F. (2008) · Cell · doi:10.1016/j.cell.2008.01.052 · Cited by 480
Targeting Tyrosine Kinases in Cancer: The Second Wave
Baselga, J. (2006) · Science · doi:10.1126/science.1125951 · Cited by 478
Spatial genomic heterogeneity within localized, multifocal prostate cancer
Boutros, P. C., Fraser, M., Harding, N. J., de Borja, R., Trudel, D., Lalonde, E., Meng, A., Hennings-Yeomans, P. H., McPherson, A., Sabelnykova, V. Y., et al. (2015) · Nature Genetics · doi:10.1038/ng.3315 · Cited by 477
Exome sequencing identifies GRIN2A as frequently mutated in melanoma
Program, N. C. S., Wei, X., Walia, V., Lin, J. C., Teer, J. K., Prickett, T. D., Gartner, J., Davis, S., Stemke-Hale, K., Davies, M. A., et al. (2011) · Nature Genetics · doi:10.1038/ng.810 · Cited by 471
Self-citationCheung, L. W. T., Hennessy, B. T., Li, J., Yu, S., Myers, A. P., Djordjevic, B., Lu, Y., Stemke-Hale, K., Dyer, M. D., Zhang, F., et al. (2011) · Cancer Discovery · doi:10.1158/2159-8290.cd-11-0039 · Cited by 470
Tumours with PI3K activation are resistant to dietary restriction
Kalaany, N. Y., & Sabatini, D. M. (2009) · Nature · doi:10.1038/nature07782 · Cited by 468
PI3K/Akt/mTOR pathway as a target for cancer therapy
Morgensztern, D., & McLeod, H. L. (2005) · Anti-Cancer Drugs · doi:10.1097/01.cad.0000173476.67239.3b · Cited by 468
High Frequency of Coexistent Mutations of PIK3CA and PTEN Genes in Endometrial Carcinoma
Oda, K., Stokoe, D., Taketani, Y., & McCormick, F. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-2620 · Cited by 466
Jhawer, M., Goel, S., Wilson, A. J., Montagna, C., Ling, Y.-H., Byun, D.-S., Nasser, S., Arango, D., Shin, J., Klampfer, L., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-5659 · Cited by 460
Critical role for the p110α phosphoinositide-3-OH kinase in growth and metabolic regulation
Foukas, L. C., Claret, M., Pearce, W., Okkenhaug, K., Meek, S., Peskett, E., Sancho, S., Smith, A. J. H., Withers, D. J., & Vanhaesebroeck, B. (2006) · Nature · doi:10.1038/nature04694 · Cited by 463
Exploring the specificity of the PI3K family inhibitor LY294002
Gharbi, S. I., Zvelebil, M. J., Shuttleworth, S. J., Hancox, T., Saghir, N., Timms, J. F., & Waterfield, M. D. (2007) · Biochemical Journal · doi:10.1042/bj20061489 · Cited by 462
Miller, T. W., Rexer, B. N., Garrett, J. T., & Arteaga, C. L. (2011) · Breast Cancer Research · doi:10.1186/bcr3039 · Cited by 462
Dazert, E., & Hall, M. N. (2011) · Current Opinion in Cell Biology · doi:10.1016/j.ceb.2011.09.003 · Cited by 460
Easton, J. B., & Houghton, P. J. (2006) · Oncogene · doi:10.1038/sj.onc.1209886 · Cited by 459
Engelman, J. A., Mukohara, T., Zejnullahu, K., Lifshits, E., Borras, A. M., Gale, C.-M., Naumov, G. N., Yeap, B. Y., Jarrell, E., Sun, J., et al. (2006) · Journal of Clinical Investigation · doi:10.1172/jci28656 · Cited by 456
Janku, F., Wheler, J. J., Westin, S. N., Moulder, S. L., Naing, A., Tsimberidou, A. M., Fu, S., Falchook, G. S., Hong, D. S., Garrido-Laguna, I., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.36.1196 · Cited by 447
Signaling by the Phosphoinositide 3-Kinase Family in Immune Cells
Okkenhaug, K. (2013) · Annual Review of Immunology · doi:10.1146/annurev-immunol-032712-095946 · Cited by 446
Targeted polypharmacology: discovery of dual inhibitors of tyrosine and phosphoinositide kinases
Apsel, B., Blair, J. A., Gonzalez, B., Nazif, T. M., Feldman, M. E., Aizenstein, B., Hoffman, R., Williams, R. L., Shokat, K. M., & Knight, Z. A. (2008) · Nature Chemical Biology · doi:10.1038/nchembio.117 · Cited by 440
Zhao, L., & Vogt, P. K. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0712169105 · Cited by 437
High frequency of PTEN, PI3K, and AKT abnormalities in T-cell acute lymphoblastic leukemia
Gutierrez, A., Sanda, T., Grebliunaite, R., Carracedo, A., Salmena, L., Ahn, Y., Dahlberg, S., Neuberg, D., Moreau, L. A., Winter, S. S., et al. (2009) · Blood · doi:10.1182/blood-2009-02-206722 · Cited by 437
Bosch, A., Li, Z., Bergamaschi, A., Ellis, H., Toska, E., Prat, A., Tao, J. J., Spratt, D. E., Viola-Villegas, N. T., Castel, P., et al. (2015) · Science Translational Medicine · doi:10.1126/scitranslmed.aaa4442 · Cited by 432
PIK3CA Mutations and Copy Number Gains in Human Lung Cancers
Yamamoto, H., Shigematsu, H., Nomura, M., Lockwood, W. W., Sato, M., Okumura, N., Soh, J., Suzuki, M., Wistuba, I. I., Fong, K. M., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-5084 · Cited by 429
Self-citationFrequent Mutation of the PIK3CA Gene in Ovarian and Breast Cancers
Levine, D. A., Bogomolniy, F., Yee, C. J., Lash, A., Barakat, R. R., Borgen, P. I., & Boyd, J. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-2142 · Cited by 422
She, Q.-B., Solit, D. B., Ye, Q., O’Reilly, K. E., Lobo, J., & Rosen, N. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.09.006 · Cited by 421
Cancer-specific mutations in PIK3CA are oncogenic in vivo
Bader, A. G., Kang, S., & Vogt, P. K. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0510857103 · Cited by 420
Hou, P., Liu, D., Shan, Y., Hu, S., Studeman, K., Condouris, S., Wang, Y., Trink, A., El-Naggar, A. K., Tallini, G., et al. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-1125 · Cited by 418
An In vivo Platform for Translational Drug Development in Pancreatic Cancer
Rubio-Viqueira, B., Jimeno, A., Cusatis, G., Zhang, X., Iacobuzio-Donahue, C., Karikari, C., Shi, C., Danenberg, K., Danenberg, P. V., Kuramochi, H., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-0113 · Cited by 414
Phosphatidylinositol 3-Kinase and Antiestrogen Resistance in Breast Cancer
Miller, T. W., Balko, J. M., & Arteaga, C. L. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.34.4879 · Cited by 413
Mechanism of Two Classes of Cancer Mutations in the Phosphoinositide 3-Kinase Catalytic Subunit
Miled, N., Yan, Y., Hon, W.-C., Perisic, O., Zvelebil, M., Inbar, Y., Schneidman-Duhovny, D., Wolfson, H. J., Backer, J. M., & Williams, R. L. (2007) · Science · doi:10.1126/science.1135394 · Cited by 410
She, Q.-B., Halilovic, E., Ye, Q., Zhen, W., Shirasawa, S., Sasazuki, T., Solit, D. B., & Rosen, N. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.05.023 · Cited by 400
Hodges, T. R., Ott, M., Xiu, J., Gatalica, Z., Swensen, J., Zhou, S., Huse, J. T., de Groot, J., Li, S., Overwijk, W. W., et al. (2017) · Neuro-Oncology · doi:10.1093/neuonc/nox026 · Cited by 404
PTEN, more than the AKT pathway
Blanco-Aparicio, C., Renner, O., Leal, J. F. M., & Carnero, A. (2007) · Carcinogenesis · doi:10.1093/carcin/bgm052 · Cited by 403
PIK3CA Mutation Associates with Improved Outcome in Breast Cancer
Kalinsky, K., Jacks, L. M., Heguy, A., Patil, S., Drobnjak, M., Bhanot, U. K., Hedvat, C. V., Traina, T. A., Solit, D., Gerald, W., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-0632 · Cited by 401
Phosphoinositide signalling in cancer: beyond PI3K and PTEN
Bunney, T. D., & Katan, M. (2010) · Nature Reviews Cancer · doi:10.1038/nrc2842 · Cited by 400
Molecular Mechanisms of Colon Cancer Progression and Metastasis: Recent Insights and Advancements
Malki, A., ElRuz, R. A., Gupta, I., Allouch, A., Vranic, S., & Al Moustafa, A.-E. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms22010130 · Cited by 398
Guo, C., Sah, J. F., Beard, L., Willson, J. K. V., Markowitz, S. D., & Guda, K. (2008) · Genes, Chromosomes and Cancer · doi:10.1002/gcc.20596 · Cited by 396
Self-citationZuo, T., Wang, L., Morrison, C., Chang, X., Zhang, H., Li, W., Liu, Y., Wang, Y., Liu, X., Chan, M. W. Y., et al. (2007) · Cell · doi:10.1016/j.cell.2007.04.034 · Cited by 395
Calvisi, D. F., Ladu, S., Gorden, A., Farina, M., Lee, J.-S., Conner, E. A., Schroeder, I., Factor, V. M., & Thorgeirsson, S. S. (2007) · Journal of Clinical Investigation · doi:10.1172/jci31457 · Cited by 393
Antitumor Activity of ZSTK474, a New Phosphatidylinositol 3-Kinase Inhibitor
Yaguchi, S.-I., Fukui, Y., Koshimizu, I., Yoshimi, H., Matsuno, T., Gouda, H., Hirono, S., Yamazaki, K., & Yamori, T. (2006) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djj133 · Cited by 387
Contributions of the Raf/MEK/ERK, PI3K/PTEN/Akt/mTOR and Jak/STAT pathways to leukemia
Steelman, L. S., Abrams, S. L., Whelan, J., Bertrand, F. E., Ludwig, D. E., Bäsecke, J., Libra, M., Stivala, F., Milella, M., Tafuri, A., et al. (2008) · Leukemia · doi:10.1038/leu.2008.26 · Cited by 385
Mirzoeva, O. K., Das, D., Heiser, L. M., Bhattacharya, S., Siwak, D., Gendelman, R., Bayani, N., Wang, N. J., Neve, R. M., Guan, Y., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-3389 · Cited by 385
Inhibition of PI3K/mTOR Leads to Adaptive Resistance in Matrix-Attached Cancer Cells
Muranen, T., Selfors, L. M., Worster, D. T., Iwanicki, M. P., Song, L., Morales, F. C., Gao, S., Mills, G. B., & Brugge, J. S. (2012) · Cancer Cell · doi:10.1016/j.ccr.2011.12.024 · Cited by 384
PDGFRs are critical for PI3K/Akt activation and negatively regulated by mTOR
Zhang, H., Bajraszewski, N., Wu, E., Wang, H., Moseman, A. P., Dabora, S. L., Griffin, J. D., & Kwiatkowski, D. J. (2007) · Journal of Clinical Investigation · doi:10.1172/jci28984 · Cited by 381
Hu, H., Juvekar, A., Lyssiotis, C. A., Lien, E. C., Albeck, J. G., Oh, D., Varma, G., Hung, Y. P., Ullas, S., Lauring, J., et al. (2016) · Cell · doi:10.1016/j.cell.2015.12.042 · Cited by 380
Rare cancer-specific mutations in PIK3CA show gain of function
Gymnopoulos, M., Elsliger, M.-A., & Vogt, P. K. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0701005104 · Cited by 376
Molecular classification of gastric cancer
Chia, N.-Y., & Tan, P. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw040 · Cited by 375
Targeting the PI3K/AKT/mTOR and Raf/MEK/ERK pathways in the treatment of breast cancer
Saini, K. S., Loi, S., de Azambuja, E., Metzger-Filho, O., Saini, M. L., Ignatiadis, M., Dancey, J. E., & Piccart-Gebhart, M. J. (2013) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2013.03.009 · Cited by 374
Discovery of GSK2126458, a Highly Potent Inhibitor of PI3K and the Mammalian Target of Rapamycin
Knight, S. D., Adams, N. D., Burgess, J. L., Chaudhari, A. M., Darcy, M. G., Donatelli, C. A., Luengo, J. I., Newlander, K. A., Parrish, C. A., Ridgers, L. H., et al. (2010) · ACS Medicinal Chemistry Letters · doi:10.1021/ml900028r · Cited by 373
Functional Analysis of PIK3CA Gene Mutations in Human Colorectal Cancer
Ikenoue, T., Kanai, F., Hikiba, Y., Obata, T., Tanaka, Y., Imamura, J., Ohta, M., Jazag, A., Guleng, B., Tateishi, K., et al. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-4114 · Cited by 369
The PI3K/AKT Pathway and Renal Cell Carcinoma
Guo, H., German, P., Bai, S., Barnes, S., Guo, W., Qi, X., Lou, H., Liang, J., Jonasch, E., Mills, G. B., et al. (2015) · Journal of Genetics and Genomics · doi:10.1016/j.jgg.2015.03.003 · Cited by 369
Lee, J. C., Vivanco, I., Beroukhim, R., Huang, J. H. Y., Feng, W. L., DeBiasi, R. M., Yoshimoto, K., King, J. C., Nghiemphu, P., Yuza, Y., et al. (2006) · PLoS Medicine · doi:10.1371/journal.pmed.0030485 · Cited by 367
Targeting the PI3K/AKT Pathway for the Treatment of Prostate Cancer
Sarker, D., Reid, A. H. M., Yap, T. A., & de Bono, J. S. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0125 · Cited by 366
Jansen, L. A., Mirzaa, G. M., Ishak, G. E., O'Roak, B. J., Hiatt, J. B., Roden, W. H., Gunter, S. A., Christian, S. L., Collins, S., Adams, C., et al. (2015) · Brain · doi:10.1093/brain/awv045 · Cited by 364
Rekhtman, N., Paik, P. K., Arcila, M. E., Tafe, L. J., Oxnard, G. R., Moreira, A. L., Travis, W. D., Zakowski, M. F., Kris, M. G., & Ladanyi, M. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-2109 · Cited by 364
The role of PTEN signaling perturbations in cancer and in targeted therapy
Keniry, M., & Parsons, R. (2008) · Oncogene · doi:10.1038/onc.2008.248 · Cited by 358
Oncogenic Roles of the PI3K/AKT/mTOR axis
Aoki, M., & Fujishita, T. (2017) · Current topics in microbiology and immunology · doi:10.1007/82_2017_6 · Cited by 355
Analysis of the tyrosine kinome in melanoma reveals recurrent mutations in ERBB4
Program, N. C. S., Prickett, T. D., Agrawal, N. S., Wei, X., Yates, K. E., Lin, J. C., Wunderlich, J. R., Cronin, J. C., Cruz, P., Rosenberg, S. A., et al. (2009) · Nature Genetics · doi:10.1038/ng.438 · Cited by 352
Self-citationPharmacologic Characterization of a Potent Inhibitor of Class I Phosphatidylinositide 3-Kinases
Raynaud, F. I., Eccles, S., Clarke, P. A., Hayes, A., Nutley, B., Alix, S., Henley, A., Di-Stefano, F., Ahmad, Z., Guillard, S., et al. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-4615 · Cited by 352
Somatic Activating PIK3CA Mutations Cause Venous Malformation
Limaye, N., Kangas, J., Mendola, A., Godfraind, C., Schlögel, M. J., Helaers, R., Eklund, L., Boon, L. M., & Vikkula, M. (2015) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2015.11.011 · Cited by 351
Chakrabarty, A., Sánchez, V., Kuba, M. G., Rinehart, C., & Arteaga, C. L. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1018001108 · Cited by 347
Metadata
- Authors
- Samuels, Y., Wang, Z., Bardelli, A., Silliman, N., Ptak, J., Szabo, S., Yan, H., Gazdar, A., Powell, S. M., Riggins, G. J., Willson, J. K. V., Markowitz, S., Kinzler, K. W., Vogelstein, B., & Velculescu, V. E.
- Venue
- Science
- Published
- 2004-04-23
- Volume
- 304
- Issue
- 5670
- Pages
- 554-554
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- OpenAlex
- W2129172946
- Cited by
- 3,437
- References
- 4
- FWCI
- 43.95
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.